CJ Bioscience. Inc. · KRX:311690

CJ Bioscience. Inc. financial statements

CJ Bioscience. Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue3.69B3.47B5.58B4.07B4.36B5.31B4.78B3.92B3.67B
Cost of revenue2.99B3.10B3.73B2.67B2.71B2.90B2.11B1.73B1.79B
Gross profit698.9M365.4M1.84B1.41B1.65B2.41B2.67B2.20B1.88B
Research and development18.1B23.2B22.8B19.2B4.85B4.98B3.40B
Selling, general and administrative1.84B10.2B9.95B13.4B6.13B5.57B3.48B3.19B2.27B
Operating income-24.8B-34.2B-32.0B-33.2B-12.2B-8.51B-4.52B-3.41B-2.62B
Depreciation and amortization4.01B4.28B5.11B3.90B1.56B1.05B731.0M439.1M500.2M
EBITDA-20.8B-30.0B-26.9B-29.3B-10.7B-7.46B-3.79B-2.97B-2.12B
Interest expense540.2M587.4M922.1M2.76B4.97B1.62B45.3M00
Income before tax-24.0B-32.8B-22.9B-34.9B-19.3B-8.76B-4.35B-3.13B-2.36B
Net income-24.0B-32.8B-22.9B-34.9B-19.3B-8.76B-4.35B-3.13B-2.36B
Earnings per share, basic-1,837.29-2,513.32-2,514.44-5,939.00-2,815.87-2,251.23-1,140.92-973.88-735.99

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents10.3B8.31B64.1B49.3B62.1B13.3B5.33B148.6K178.8K
Short-term investments40.5B67.0B18.0B26.0B25.7B20.0M20.0M
Receivables418.8M334.1M303.5M303.8M233.6M99.5M194.1M301.3M258.3M
Inventory185.1M128.8M157.8M76.2M145.8M364.3M98.7M145.8M111.6M
Current assets52.5B76.8B65.2B50.9B81.6B41.1B31.6B11.5B13.4B
Property, plant and equipment8.91B12.7B14.4B9.86B20.0B1.73B920.8M1.25B
Total assets72.3B99.6B91.1B91.4B116.4B73.4B33.7B12.8B15.0B
Accounts payable378.3M220.8M122.8M336.7M287.7M708.9M288.9M
Current liabilities14.6B18.5B14.7B35.0B23.8B3.00B2.31B1.88B1.62B
Long-term debt0035.1B
Total debt35.6B368.2M
Total liabilities18.7B21.9B19.6B41.7B28.5B38.9B2.89B2.06B1.83B
Shareholders' equity53.6B77.8B71.5B49.7B87.9B34.5B30.9B10.8B13.2B
Shares outstanding13.1M13.1M9.11M5.88M6.84M3.89M3.81M3.22M3.21M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-23.4B-27.8B-24.9B-21.0B-8.44B-7.98B-2.51B-2.03B-1.57B
Capital spending-75.9M-583.6M-16.4B-4.14B-952.7M-12.0B-427.2M-156.8M-602.7M
Free cash flow-23.5B-28.3B-41.3B-25.9B-9.42B-26.8B-2.96B-2.19B-2.17B
Cash from investing-67.6B16.7B7.16B6.45B-26.5B-26.2B-160.8M11.5B
Cash from financing39.5B22.9B1.02B50.7B42.3B23.3B19.4M-18.6M
Share buybacks40.0B45.0B50.0M73.5B826.5M23.6B25.3M99.3M
Change in cash2.03B-55.8B14.8B-12.7B48.8B7.90B-5.39B-2.15B9.89B